StockData
BlossomHill Therapeutics, Inc. logo

BlossomHill Therapeutics, Inc. (BLSM) stock

BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$14.59−0.54 (-3.57%)

Close on Nov 18, 2026Market cap $37.18MP/E –Yield –

BlossomHill Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$24.67M–
Q2 FY2025Jun 30, 2025-$14.10M–

More BlossomHill Therapeutics figures

See a number that looks wrong?